Document Detail

Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling.
MedLine Citation:
PMID:  20497460     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Coronary artery disease (CAD) represents the most relevant cause of death and morbidity in the adult population of developed and developing countries. During the last decades, a strong research effort has been performed to identify more selective markers and better assess the cardiovascular risk in both primary and secondary prevention.
MATERIALS AND METHODS: This review updates current knowledge regarding the pathophysiological relevance as possible markers of coronary calcification of the receptor activator of nuclear factor-kappa ligand (RANKL)/osteoprotegerin (OPG) system. Furthermore, the potential clinical use of both RANKL/OPG and coronary calcium score (CAC) to assess cardiovascular vulnerability has been discussed.
RESULTS: Emerging evidence indicates that atherosclerotic plaque calcification is positively correlated with vulnerability. Several inflammatory mediators have been shown to modulate arterial calcification, thus increasing the risk of plaque rupture. Among these factors, RANKL/OPG axis might be of particular interest as a promising biomarker of plaque vulnerability in subjects with diffuse coronary calcification.
CONCLUSION: Together with clinical parameters of coronary calcification (such as CAC), circulating RANKL/OPG levels could contribute to better assess and predict cardiac events.
Alessandra Quercioli; Fabrizio Montecucco; Maria Bertolotto; Luciano Ottonello; Aldo Pende; François Mach; Franco Dallegri
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-05-23
Journal Detail:
Title:  European journal of clinical investigation     Volume:  40     ISSN:  1365-2362     ISO Abbreviation:  Eur. J. Clin. Invest.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-19     Completed Date:  2011-01-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0245331     Medline TA:  Eur J Clin Invest     Country:  England    
Other Details:
Languages:  eng     Pagination:  645-54     Citation Subset:  IM    
Division of Cardiology, Department of Medicine, Geneva University Hospital, Foundation for Medical Researches, Geneva, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood,  metabolism*
Calcinosis / blood*,  metabolism
Cardiovascular Diseases / etiology*
Coronary Artery Disease / blood,  complications*
Osteoprotegerin / blood*,  metabolism
RANK Ligand / blood*
Receptor Activator of Nuclear Factor-kappa B / blood*
Risk Factors
Reg. No./Substance:
0/Biological Markers; 0/Osteoprotegerin; 0/RANK Ligand; 0/Receptor Activator of Nuclear Factor-kappa B

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evidence of validity in a new method for measurement of dexterity in children and adolescents.
Next Document:  Impaired cardiovascular response to standing in chronic fatigue syndrome.